The stock has a 36-month beta value of 0.97. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for AKTX is 5.04M, and at present, short sellers hold a 0.12% of that float. On April 02, 2024, the average trading volume of AKTX was 10.42K shares.
AKTX) stock’s latest price update
Akari Therapeutics Plc ADR (NASDAQ: AKTX) has experienced a decline in its stock price by -19.03 compared to its previous closing price of 1.87. However, the company has seen a fall of -16.57% in its stock price over the last five trading days. GlobeNewsWire reported 2023-12-14 that NEW YORK and BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that President and CEO Rachelle Jacques will present a company overview for in-person and virtual attendees at Biotech Showcase taking place in San Francisco, CA January 8-10, 2024, adjacent to the J.P. Morgan Healthcare Conference 2024. Akari management will attend one-on-one meetings during the conferences.
AKTX’s Market Performance
AKTX’s stock has fallen by -16.57% in the past week, with a monthly drop of -35.74% and a quarterly drop of -49.83%. The volatility ratio for the week is 10.28% while the volatility levels for the last 30 days are 8.03% for Akari Therapeutics Plc ADR The simple moving average for the past 20 days is -25.96% for AKTX’s stock, with a -53.01% simple moving average for the past 200 days.
Analysts’ Opinion of AKTX
Many brokerage firms have already submitted their reports for AKTX stocks, with B. Riley FBR repeating the rating for AKTX by listing it as a “Buy.” The predicted price for AKTX in the upcoming period, according to B. Riley FBR is $3 based on the research report published on January 04, 2019 of the previous year 2019.
B. Riley FBR Inc., on the other hand, stated in their research note that they expect to see AKTX reach a price target of $3. The rating they have provided for AKTX stocks is “Neutral” according to the report published on February 08th, 2018.
AKTX Trading at -35.12% from the 50-Day Moving Average
After a stumble in the market that brought AKTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.55% of loss for the given period.
Volatility was left at 8.03%, however, over the last 30 days, the volatility rate increased by 10.28%, as shares sank -33.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -47.57% lower at present.
During the last 5 trading sessions, AKTX fell by -16.57%, which changed the moving average for the period of 200-days by -51.60% in comparison to the 20-day moving average, which settled at $2.0010. In addition, Akari Therapeutics Plc ADR saw -51.60% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for AKTX
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.95.
Conclusion
To sum up, Akari Therapeutics Plc ADR (AKTX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
